PPARG Negatively Modulates Six2 in Tumor Formation of Clear Cell Renal Cell Carcinoma.

Substantial research has revealed that peroxisome proliferator-activated receptor-gamma (PPARG) plays a critical role in glucose homeostasis and lipid metabolism, and recent studies have shown different effects in the progression of different tumors. However, the role of PPARG and its target gene in clear cell renal cell carcinoma (ccRCC) are incompletely understood. Clinical data revealed abnormal glucolipid metabolism in primary ccRCC samples. In addition, transcriptional profiling indicated that PPARG expression was positively correlated, whereas Six2 expression was negatively correlated with the overall survival of ccRCC patients. Staining showed that PPARG was mainly expressed in tumor cell cytoplasm, and Six2 was localized to the nuclei. In a ccRCC cell line, PPARG activation promoted cell apoptosis, inhibited cell migration and proliferation, and reduced Six2 expression. Mechanistically, overexpressing Six2 downregulated E-cadherin expression and cell apoptosis, but PPARG activation reversed those effects. Taken together, PPARG promotes apoptosis and suppresses the migration and proliferation of ccRCC cells by inhibiting Six2. These findings reveal that the PPARG/Six2 axis acts as a central pathobiological mediator of ccRCC formation and as a potential therapeutic target for the treatment of patients with ccRCC.

[1]  Jian-hua Li,et al.  Six2 is negatively correlated with good prognosis and decreases 5-FU sensitivity via suppressing E-cadherin expression in hepatocellular carcinoma cells. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  D. Steger,et al.  PPARγ is dispensable for clear cell renal cell carcinoma progression , 2018, Molecular metabolism.

[3]  A. Oshlack,et al.  Haploinsufficiency for the Six2 gene increases nephron progenitor proliferation promoting branching and nephron number. , 2017, Kidney international.

[4]  Evita T. Sadimin,et al.  Renal cell carcinoma: the search for a reliable biomarker. , 2017, Translational cancer research.

[5]  Y. Weng,et al.  TβRII Regulates the Proliferation of Metanephric Mesenchyme Cells through Six2 In Vitro , 2017, International journal of molecular sciences.

[6]  Charles Swanton,et al.  Renal cell carcinoma , 2017, Nature Reviews Disease Primers.

[7]  B. Saez,et al.  Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action , 2017, Targeted Oncology.

[8]  Yue Zhou,et al.  Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2/M-phase arrest, independent of PPAR-γ pathway. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  N. Samadi,et al.  Six Family of Homeobox Genes and Related Mechanisms in Tumorigenesis Protocols , 2016, Tumori.

[10]  G. Ayers,et al.  SIX2 Effects on Wilms Tumor Biology1 , 2014, Translational oncology.

[11]  B. Grygiel-Górniak Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review , 2014, Nutrition Journal.

[12]  J. M. Suh,et al.  PPARγ signaling and metabolism: the good, the bad and the future , 2013, Nature Medicine.